Evidence map›Paper›PMID 28801475›Full record

ArticleDiabetes care2017

Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1 RA and DPP-4 Therapies in Patients With Type 2 Diabetes.

Ginger S Carls, Edward Tuttle, Ruo-Ding Tan, Johnny Huynh, John Yee, Steven V Edelman, William H Polonsky

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Diabetes care, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT05535322. Cited by 88 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05535322 completed

Real-world Evaluation of GLP-1 Receptor Agonists (GLP-1RA) on Efficacy and Persistence, Adherence and Therapeutic Inertia Among Type 2 Diabetes Adults With Obesity in the Department of Health of Valencia Clínico-Malvarrosa

Ran2014Enrolled26,944Registered outcomes12Posted comparisons0ConditionsObesity, Type 2 DiabetesArmsGLP-1RA, Insulin, Miscellany, SGLT2i
PMID 21457427PMID 29364585PMID 32347181PMID 32295809PMID 31673896PMID 31422062PMID 31028689PMID 30677504PMID 30291013PMID 29675797PMID 28834075PMID 28070733other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

88 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Predicting Medication Nonadherence in Older Adults With Difficult-to-Treat Depression in the IRL-GRey Randomized Controlled Trial.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2022
    Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review

28 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ginger S CarlsAnalysis Group, Menlo Park, CA.ORCID 0000-0003-2724-2731
Edward TuttleAnalysis Group, Menlo Park, CA.
Ruo-Ding TanAnalysis Group, Menlo Park, CA ruo-ding.tan@analysisgroup.com.
Johnny HuynhAnalysis Group, Menlo Park, CA.
John YeeIntarcia Therapeutics, Boston, MA.
Steven V EdelmanDivision of Endocrinology and Metabolism, School of Medicine, University of California, San Diego, San Diego, CA.
William H PolonskyDepartment of Psychiatry, University of California, San Diego, San Diego, CA.ORCID 0000-0001-9064-6144

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe objective of this study was to estimate and explain the gap between clinical efficacy and real-world (RW) effectiveness of type 2 diabetes medications. RESEARCH DESIGN AND

methodsThis mixed-methods quasi-experimental study used retrospective claims (Optum/Humedica) to compare the change in HbA

resultsRW patients initiating a GLP-1 RA (

conclusionsPoor medication adherence is primarily why RW effectiveness is significantly less than RCT efficacy, suggesting an urgent need to effectively address adherence among patients with type 2 diabetes.

Indexed as

Diabetes Mellitus, Type 2Dipeptidyl Peptidase 4FemaleFollow-Up StudiesGlucagon-Like Peptide 1Glycated HemoglobinHumansHypoglycemic AgentsIncretinsMaleMedication AdherenceMiddle AgedRandomized Controlled Trials as TopicRetrospective StudiesSensitivity and SpecificityDipeptidyl Peptidase 4DPP4 protein, humanGlucagon-Like Peptide 1Glycated HemoglobinHypoglycemic AgentsIncretins

Identifiers

PMID28801475

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.